Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis

Federico Verde, Petra Steinacker, Patrick Oeckl, Jochen H. Weishaupt, Angela Rosenbohm, Vincenzo Silani, Albert C. Ludolph, Markus Otto

Research output: Contribution to journalArticlepeer-review


Chromogranin A (CgA) is a protein found in large dense-core vesicles of neuroendocrine cells and neurons and regulating secretion. A relevance to amyotrophic lateral sclerosis (ALS) was suggested as its overexpression accelerates disease onset in model systems and it interacts with mutant forms of SOD1. Recently, increased cerebrospinal fluid (CSF) CgA levels have been reported in ALS patients relative to controls. With the aim of confirming this finding, we measured CgA and phosphorylated neurofilament heavy chain (pNFH), an established ALS biomarker, in the CSF of 32 ALS patients and 32 disease controls. ALS patients had clearly increased pNFH levels (p < 0.0001), while CgA levels were only modestly lower relative to controls (p = 0.0265), with wide value overlap and consequently poor discriminative performance. CgA did not correlate with any disease parameters among ALS patients. Our findings suggest that CgA is not a promising clinical biomarker for ALS.

Original languageEnglish
Pages (from-to)21-22
Number of pages2
JournalNeurobiology of Aging
Publication statusPublished - Jul 1 2018


  • Amyotrophic lateral sclerosis (ALS)
  • Cerebrospinal fluid (CSF)
  • Chromogranin A (CgA)
  • Phosphorylated neurofilament heavy chain (pNFH)

ASJC Scopus subject areas

  • Neuroscience(all)
  • Ageing
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology


Dive into the research topics of 'Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis'. Together they form a unique fingerprint.

Cite this